PRECISION BIOLOGICS TO PRESENT AT 7th INTERNATIONAL NEOANTIGEN SUMMIT, AMSTERDAM, NETHERLANDS, APRIL 29 – May 1, 2024
7th INTERNATIONAL NEOANTIGEN SUMMIT, AMSTERDAM, NETHERLANDS, APRIL 29 – May 1, 2024
Accelerating Robust, Durable & Clinically Effective Neoantigens to the Patient – Supercharging Neoantigen-Based Therapeutics & Cancer Vaccines Through Optimised Neoantigen Prediction & Streamlined Clinical Translation for Faster Approval
Day 2; Optimising Combination Therapies by Deep Diving into Mechanism of Action & Combination Strategies for More Successful, Effective & Safer Therapies
Panel Discussion: Evaluating Different Combination Strategies to Develop More Effective Cancer Treatments for Curing the Patients in Need, 2:30pm
– Which of the current state of the art immunotherapies are likely to continue well with neoantigen therapies?
– Beyond checkpoint inhibitors, what combinations seem the most promising?
– Are there certain combinations which work better for different stages of cancer?
– Discussing combining neoantigen therapies with PD-L1 therapies, chemotherapies and immunoglobins
Panelist: PHILIP ARLEN, President & Chief Executive Officer, Precision Biologics, Inc.
Presentation: 4pm
Delving into the Mechanism of Action of Neoantigen Antibodies to Aid the Development of Highly Effective Combination Strategy Towards More Successful Therapies
- What is the mechanism of action of a neoantigen antibody being used in combination?
- How to effectively use the neoantigen antibody: should it be applied before the checkpoint inhibitor or after?
- Would it be beneficial to combine with more than one other approach?
Presenter: PHILIP ARLEN, President & Chief Executive Officer, Precision Biologics, Inc.